Vitamin D and breast cancer risk: evidence, limitations, and practical messages

Updated and contextualized version of an article originally published on June 21, 2021
The article retains its original focus by presenting it through a scholarly and accessible perspective, supported by verifiable references.

Authors

• Dr. A. Colonnese – Nutrition biologist
• Roberto Panzironi –Independent researcher 

Note editoriali

• First publication: June 21, 2021
• Last update: April 20, 2026
• Version: 2026 narrative revision  

Abstract: what does science say?

“Vitamin D” (primarily measured as 25-hydroxyvitamin D in the blood) has been proposed as a factor associated with a reduced risk of various cancers, including breast cancer. Evidence includes observational studies that find inverse associations between serum 25(OH)D concentrations and cancer incidence or mortality, and some evidence from small trials where vitamin D supplementation (sometimes combined with calcium) has been associated with a reduction in neoplastic events. On the other hand, large trials and recent reviews report heterogeneous results: some show no significant reductions in total cancer incidence, while secondary analyses or subgroups suggest possible effects on cancer mortality or in populations with initial deficiency. The effect strongly depends on the study design (observational vs. randomized), the dose, the method of administration (daily doses vs. bolus), the initial nutritional status, body mass index, and other contextual factors. In summary, the literature supports biological plausibility and epidemiological associations, but does not allow for a generalized causal relationship that vitamin D reduces breast cancer risk by 90%.

Observational Evidence and Clinical Trials

Large-scale observational studies have reported correlations between higher 25(OH)D levels and a lower risk of developing certain cancers or better outcomes after diagnosis; however, associations do not inherently imply causality and may reflect confounding from lifestyle or general health status. Some randomized trials provide conflicting results: a trial on a smaller population observed a decrease in neoplastic events with vitamin D supplementation along with calcium [1]. Larger projects, such as the VITAL trial conducted on older adults, did not show a statistically significant reduction in the total incidence of cancer with 2000 IU/day, but suggested possible benefits on cancer mortality in secondary analyses or in subgroups [2]. A trial on elderly women, conducted with up to 4 years of follow-up, did not show a significant reduction in the overall incidence of tumors when comparing supplementation and placebo [3].

Meta-analyses and Synthesis of Evidence

Systematic reviews and meta-analyses specific to breast cancer report heterogeneous results: some observational meta-analyses document an inverse association between 25(OH)D concentration and the risk or mortality from breast cancer [4][5]. However, when considering only randomized trials, the evidence is weaker and dependent on study characteristics (dose, duration, baseline status of participants) [6][7]. Recent methodological work emphasizes how the design of RCTs and the choice of endpoint can influence the ability to detect a real effect of supplementation [8].

Plausible biological mechanisms

There are biological reasons that make a role for vitamin D in regulating cell growth and immune modulation plausible. The active metabolite 1,25-(OH)2D interacts with the vitamin D receptor (VDR) present in many tissues and can influence processes such as cell differentiation, cell cycle, apoptosis, and inflammation. These effects have been observed in laboratory studies on cells and animal models and offer a mechanistic framework consistent with the hypothesis that adequate vitamin D levels may contribute to reducing abnormal cell proliferation. However, translating these mechanisms into clinical effects in humans requires robust evidence from well-designed trials: many molecules show in vitro effects that do not translate into significant clinical results when tested in complex populations. Furthermore, systemic factors such as glucose metabolism, inflammatory status, and hormonal balance can modulate the action of vitamin D and complicate the relationship between serum biomarkers and disease risk.

Interaction with other factors

The biological impact of vitamin D is influenced by variables such as initial nutritional status, body mass index (obesity is associated with lower serum values), genetic factors, sun exposure, and concomitant calcium intake. The form of administration (cholecalciferol D3 vs ergocalciferol D2), frequency (daily dose vs intermittent large doses), and duration of the intervention modulate the increase in 25(OH)D and, likely, any observable clinical effects.

Who may be at higher risk of deficiency and why this matters

Some groups frequently have 25(OH)D levels below the thresholds considered "sufficient": people with dark skin, individuals who spend little time outdoors, residents at high latitudes, obese subjects, the elderly, and people with chronic kidney disease or conditions that reduce intestinal absorption. In these contexts, deficiency can affect bone metabolism, muscle function, and potentially systemic processes related to immune response. From a clinical perspective, assessing vitamin status in at-risk individuals is an established and useful procedure for deciding on targeted interventions: supplementation in those who are deficient corrects the biological data and can prevent known consequences such as osteomalacia or rickets. The link between correcting deficiency and reducing cancer risk, however, remains a hypothesis that requires further confirmation, especially with trials that use 25(OH)D targets and not just fixed doses.

What it means in practice

For the general public, the practical message is cautious and concrete: vitamin D is important for bone health and has plausible biological roles in controlling cell growth, but current evidence does not justify absolute claims and extreme percentages (e.g., "reduces breast cancer risk by 90%"). For those who are concerned or at risk of deficiency, the correct approach is to talk to their doctor: measure 25(OH)D levels, consider the individual causes of the deficiency, and evaluate the appropriateness of supplementation and the most appropriate dose. National and international guidelines provide reference ranges and safety limits (for example, the tolerable upper limit in pregnancy and for adults), while specific cancer therapies must always be guided by an oncologist.

Communication tips for patients

If you are a general person: avoid self-diagnosis or self-treatment based on unverified information; consult your doctor before starting high-dose supplements. If you have a cancer diagnosis: discuss with your oncology team before taking supplements; the evidence on their specific impact on survival or recurrence is still evolving and may interact with ongoing treatments.

Key takeaways

• Vitamin D plays important biological roles; adequate levels are beneficial for bone and muscle health.
• Observational associations exist between 25(OH)D and the incidence/prognosis of certain cancers, including breast cancer, but association is not causation.
• Some RCTs suggest beneficial effects on oncological outcomes in specific contexts, but larger trials have heterogeneous results; context (dose, baseline status) is crucial. [1][2][3]
• Assessing and correcting deficiency in at-risk individuals is a reasonable practice; oncological therapeutic decisions always require specialist advice.

Limitations of Evidence

It is important to distinguish between observational studies (which describe associations) and randomized controlled trials (which can approach causal evidence). Observational studies on vitamin D and cancer are susceptible to confounding (e.g., physical activity, nutritional status, sun exposure), selection bias, and variable biomarker measurement. Clinical trials often have limitations: dosages not adequate to correct deficiency, populations with already sufficient baseline levels, short follow-up duration, or effects diluted by personal use of supplements outside the protocol. Meta-analyses and synthetic reviews sometimes combine heterogeneous studies, reducing the certainty of conclusions. Therefore, every interpretation requires caution and contextualization.

Editorial conclusion

Current scientific literature indicates that vitamin D is a biologically relevant element for health and that there are interesting signals regarding its possible role in the prevention and prognosis of some cancers, including breast cancer. However, the evidence does not support categorical claims such as a 90% reduction in breast cancer risk for the general population. The most prudent and evidence-based strategy is: measure vitamin status in at-risk individuals, correct deficiency under medical supervision, and consider ongoing research for more specific decisions. Further well-designed trials and studies targeting 25(OH)D levels (not just fixed doses) are needed to clarify the preventive and therapeutic effects of vitamin D in cancer.

SCIENTIFIC RESEARCH

1. Lappe JM, Travers‑Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85(6):1586–1591. https://doi.org/10.1093/ajcn/85.6.1586
2. Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019;380(1):33–44. https://doi.org/10.1056/NEJMoa1809944
3. Lappe JM, Travers‑Gustafson D, Davies KM, et al. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA. 2017;317(12):1234–1243. https://doi.org/10.1001/jama.2017.2115
4. Zhou B, Luo Y, Li C, et al. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014;110:2775–2783. https://doi.org/10.1038/bjc.2014.175
5. Zhou W, He Y, et al. Serum 25‑hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. Eur J Cancer. 2014;50:2208–2218. https://doi.org/10.1016/j.ejca.2014.02.006
6. Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double‑blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res. 2011;26(10):2341–2357. https://doi.org/10.1002/jbmr.463
7. Wang M, et al. 25‑Hydroxyvitamin D and Total Cancer Incidence and Mortality: A Meta‑Analysis of Prospective Cohort Studies. Nutrients. 2019;11(10):2295. https://doi.org/10.3390/nu11102295
8. Liu J, et al. Vitamin D supplementation and total cancer incidence and mortality by dosing strategies: meta‑analysis. Br J Cancer. 2022; (Article) https://doi.org/10.1038/s41416-022-01850-2